Globe Newswire (Mon, 1-Jun 8:00 AM ET)
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Globe Newswire (Mon, 11-May 4:05 PM ET)
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
Globe Newswire (Thu, 30-Apr 8:00 AM ET)
Elicio Therapeutics Reports Inducement Grants
Globe Newswire (Thu, 16-Apr 8:00 AM ET)
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Globe Newswire (Thu, 12-Mar 4:05 PM ET)
Market Chameleon (Fri, 14-Nov 4:10 AM ET)
Elicio Therapeutics Stock Drops Following Recent Direct Offering Announcement
Market Chameleon (Thu, 30-Jan 10:26 AM ET)
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Elicio Therapeutics trades on the NASDAQ stock market under the symbol ELTX.
As of June 3, 2026, ELTX stock price climbed to $11.97 with 50,971 million shares trading.
ELTX has a beta of 1.35, meaning it tends to be more sensitive to market movements. ELTX has a correlation of 0.04 to the broad based SPY ETF.
ELTX has a market cap of $228.46 million. This is considered a Small Cap stock.
In the last 3 years, ELTX traded as high as $22.65 and as low as $2.96.
The top ETF exchange traded funds that ELTX belongs to (by Net Assets): VTI, VXF, IWC.
ELTX has outperformed the market in the last year with a price return of +54.5% while the SPY ETF gained +28.7%. However, in the short term, ELTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -13.5% vs +10.3% return in SPY. But in the last 2 weeks, ELTX shares have fared better than the market returning +30.5% compared to SPY +2.9%.
ELTX support price is $10.91 and resistance is $12.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELTX shares will trade within this expected range on the day.
